Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）于 2019 年底在中国首次报告，是导致 2019 年冠状病毒病（COVID-19）大流行的病原体。为减轻该病毒对公共卫生、经济和社会的影响，急需开发疫苗。在这里，我回顾了针对 SARS-CoV-2 的疫苗开发情况。当病毒的遗传序列于 2020 年 1 月初可用时，疫苗的开发就开始了，而且进展速度前所未有：一项 I 期试验于 2020 年 3 月开始，目前有超过 180 种疫苗处于不同的开发阶段。几种候选疫苗的 I 期和 II 期试验数据已经可用，许多疫苗已经进入 III 期试验。到目前为止，可用的数据表明，有效的、安全的疫苗可能会在几个月内而不是几年内问世。
